Literature DB >> 26795418

Treat and extend regimen with aflibercept for choroidal neovascularization in angioid streaks.

T Diago1.   

Abstract

Mesh:

Substances:

Year:  2016        PMID: 26795418      PMCID: PMC5108543          DOI: 10.1038/eye.2015.283

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  2 in total

1.  Intravitreal aflibercept for choroidal neovascularisation in angioid streaks.

Authors:  S Vaz-Pereira; L Collaço; G De Salvo; P van Zeller
Journal:  Eye (Lond)       Date:  2015-05-29       Impact factor: 3.775

2.  Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks.

Authors:  Ebru Esen; Selcuk Sizmaz; Nihal Demircan
Journal:  Indian J Ophthalmol       Date:  2015-07       Impact factor: 1.848

  2 in total
  4 in total

1.  Intravitreal aflibercept for choroidal neovascularisation in angioid streaks.

Authors:  S Vaz-Pereira; L Collaço; G De Salvo; P van Zeller
Journal:  Eye (Lond)       Date:  2016-01-22       Impact factor: 3.775

2.  Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study.

Authors:  Martin Gliem; Johannes Birtel; Philipp Herrmann; Rolf Fimmers; Moritz Berger; Christoph Coch; Almut Wingen; Frank G Holz; Peter Charbel Issa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-20       Impact factor: 3.117

3.  Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab.

Authors:  Olga E Makri; Foteini N Tsapardoni; Panagiotis Plotas; Athina Pallikari; Constantine D Georgakopoulos
Journal:  Int Med Case Rep J       Date:  2018-09-18

4.  Clinical characteristics and treatment outcomes of angioid streak associated choroidal neovascular membrane (AS-CNV): a Zambian case series.

Authors:  Kshitiz Kumar; Santosh Balasubramaniam; Amar Agarwal
Journal:  Pan Afr Med J       Date:  2020-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.